ImmunityBio (IBRX) Cash & Current Investments (2014 - 2026)

ImmunityBio (IBRX) has reported Cash & Current Investments for 13 consecutive years, with $380.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 518.4% year-over-year to $380.9 million; the TTM figure through Mar 2026 stood at $380.9 million (up 518.4% YoY), while the FY2025 annual figure was $242.8 million, up 62.09% from the prior year.
• Cash & Current Investments rose to $380.9 million in Q1 2026 per IBRX's latest filing, from $242.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $380.9 million in Q1 2026 and bottomed at $46.0 million in Q2 2023.
• Historically, Cash & Current Investments has averaged $167.8 million across 5 years, with a median of $153.7 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 66.2% — and 2026, when it jumped 518.4%.
• ImmunityBio's Cash & Current Investments stood at $107.2 million in 2022, then surged by 148.6% to $266.5 million in 2023, then tumbled by 43.78% to $149.8 million in 2024, then surged by 62.09% to $242.8 million in 2025, then surged by 56.86% to $380.9 million in 2026.
• Business Quant data shows IBRX's Cash & Current Investments at $380.9 million in Q1 2026, $242.8 million in Q4 2025, and $257.8 million in Q3 2025.